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CB1 cannabinoid receptors are expressed on vagal afferent fibers and neurons
within the solitary tract nucleus (NTS), providing anatomical evidence for their role in
arterial baroreflex modulation. To better understand the relationship between the brain
renin-angiotensin system (RAS) and endocannabinoid expression within the NTS, we
measured dorsal medullary endocannabinoid tissue content and the effects of CB1
receptor blockade at this brain site on cardiac baroreflex sensitivity (BRS) in ASrAOGEN
rats with low glial angiotensinogen, normal Sprague-Dawley rats and (mRen2)27 rats
with upregulated brain RAS expression. Mass spectrometry revealed higher levels of the
endocannabinoid 2-arachidonoylglycerol in (mRen2)27 compared to ASrAOGEN rats
(2.70 ± 0.28 vs. 1.17 ± 0.09 ng/mg tissue; P < 0.01), while Sprague-Dawley rats
had intermediate content (1.85 ± 0.27 ng/mg tissue). Microinjection of the CB1receptor
antagonist SR141716A (36 pmol) into the NTS did not change cardiac BRS in
anesthetized Sprague-Dawley rats (1.04 ± 0.05 ms/mmHg baseline vs. 1.17 ± 0.11
ms/mmHg after 10 min). However, SR141716A in (mRen2)27 rats dose-dependently
improved BRS in this strain: 0.36 pmol of SR141716A increased BRS from 0.43 ± 0.03
to 0.71 ± 0.04 ms/mmHg (P < 0.001), and 36 pmol of SR141716A increased BRS from
0.47 ± 0.02 to 0.94 ± 0.10 ms/mmHg (P < 0.01). In contrast, 0.36 pmol (1.50 ± 0.12
vs. 0.86 ± 0.08 ms/mmHg; P < 0.05) and 36 pmol (1.38 ± 0.16 vs. 0.46 ± 0.003
ms/mmHg; P< 0.01) of SR141716A significantly reduced BRS in ASrAOGEN rats. These
observations reveal differential dose-related effects of the brain endocannabinoid system
that influence cardiovagal BRS in animals with genetic alterations in the brain RAS.
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INTRODUCTION
Tonic overactivation of the endocannabinoid system is
implicated in the maintenance of cardiovascular diseases
and its risk factors, including hypertension, atherosclerosis
and metabolic syndrome (Pacher et al., 2006; Després, 2007).
These adverse conditions are associated with dysfunction of the
arterial baroreflex and reduced heart rate variability, themselves
indices of general morbidity and mortality (Thayer and Lane,
2007). Baroreflex sensitivity (BRS) for control of heart rate (HR),
measured as the bradycardia evoked in response to increases
in mean arterial pressure (MAP), is an important indicator
of parasympathetic activity and vagus nerve function, and its
impairment often precedes the development of cardiovascular
disease (Thayer and Lane, 2007).
The G protein-coupled CB1 cannabinoid receptor is widely
expressed in the central nervous system (CNS) and in peripheral
tissues, enabling the activated receptor to regulate a variety of
physiological functions including blood pressure and heart rate
(Pertwee, 2006). Presynaptic CB1 receptors are densely expressed
in the solitary tract nucleus (NTS) of the dorsomedial medulla,
the primary termination site for baroreceptor afferent neurons
relaying sensory information from the periphery, as well as
in vagal afferent neurons originating in the nodose ganglion
(Mailleux and Vanderhaeghen, 1992; Burdyga et al., 2010).
Several studies show that exogenously-applied anandamide,
one of two primary endocannabinoid signaling molecules
along with 2-arachidonoylglycerol (2-AG), within the NTS
modulates baroreflex-evoked suppression of renal sympathetic
nerve activity in rats by altering release of the inhibitory
neurotransmitter GABA (Seagard et al., 2004; Brozoski et al.,
2005). Therefore, the brain endocannabinoid system may
influence BRS through the modulation of neurotransmitter
release in brain sites regulating effects on the baroreflex.
There is growing evidence for interactions between the
endocannabinoid system and the hypertensive actions of the
renin-angiotensin system (RAS) (Rozenfeld et al., 2011; Szekeres
et al., 2012). Chronic systemic blockade of CB1 receptors results
in a reduction in blood pressure and improvement in indices
of the parasympathetic component of the BRS for control of
heart rate in the (mRen2)27 transgenic model of RAS-dependent
hypertension (Schaich et al., 2014). In addition, attenuation of
BRS following acute injection of Ang II into the NTS of Sprague-
Dawley (SD) rats is prevented by prior NTS blockade of CB1
receptors (Diz et al., 2015). However, no studies to date have
investigated the role of the endocannabinoid system in the NTS
of animals with long-term alterations in brain RAS expression.
To test our hypothesis that endocannabinoid content
influences cardiac BRS at the level of the NTS in animals
with altered brain RAS expression, we studied dorsal medullary
endocannabinoid content and function in hemizygous transgenic
(mRen2)27 rats, a monogenetic model of Ang II-dependent
hypertension in which the mouse Ren2 renin gene was
transfected into the genome of the normotensive Hannover
SD rat. These rats have a phenotype of chronic hypertension
while conscious with markedly impaired BRS for control of
HR compared to SD controls (Bader et al., 1992; Borgonio
et al., 2001). In contrast, transgenic ASrAOGEN rats with low
brain angiotensinogen, resulting from glial overexpression of an
angiotensinogen antisense oligonucleotide against a Hannover
SD background, exhibit significantly enhanced resting BRS
compared to SD rats (Schinke et al., 1999; Kasper et al., 2005).
These strains provide insights into the contribution of the
brain RAS and its influence on factors involved in regulation
of BRS (Sakima et al., 2007; Diz et al., 2008) and were used
to provide functional and biochemical evidence for altered
endocannabinoid tone at the level of the NTS.
METHODS
Animals
Experiments were performed in 15- to 20-week-old male
Hannover SD (N = 15), and hemizygous transgenic (mRen2)27
(N = 18) and TGR(ASrAOGEN)680 (ASrAOGEN; N = 17) rats
obtained from the Hypertension & Vascular Research Center
colony at Wake Forest School of Medicine (Winston-Salem,
NC). All microinjection experiments were performed in animals
between 16 and 20 weeks of age. Mass spectrometry and reverse
transcriptase quantitative polymerase chain reaction (RT-qPCR)
were performed in tissue samples from separate groups of 15-
week-old animals. Animals were housed two per cage in a
humidity- and temperature-controlled room with ad libitum
access to food (standard chow) and water. The colony was
maintained on a 12-h light/dark cycle (lights on at 6:00 a.m.).
All experimental procedures were approved by the Institutional
Animal Care and Use Committee of Wake Forest School of
Medicine.
Surgical Procedures and Hemodynamic
Measures
As previously reported (Sakima et al., 2005, 2007; Arnold
et al., 2008, 2009), rats were anesthetized with intraperitoneal
combination urethane-chloralose cocktail (750mg and 35mg
per kg, respectively). Intravenous supplemental doses diluted
to 3:7 with saline were given as needed. Polyethylene catheters
(polyethylene-10 and −50 tubing; Becton, Dickinson and
Company, Franklin Lakes, NJ) were inserted into the femoral
artery and vein, with the venous catheter proximal end positioned
near the right atrium, for measurement of cardiovascular
parameters and administration of drugs, respectively. Rats were
then placed in a stereotaxic frame with the head tilted at
a 45◦ downward angle for surgical exposure of the dorsal
medulla oblongata by incision of the atlanto-occipital lobe. Rats
breathed a mixture of 30% oxygen and 70% room air with body
temperature maintained at 37 ± 1◦C. An equilibration period
of approximately 30 min was allowed after surgical procedures
before baseline BRS measurements began. A data acquisition
system (BIOPAC Systems Inc.; AcqKnowledge software v.3.8.1;
Goleta, CA) recorded and digitized pulsatile arterial pressure
(AP) and mean AP (MAP). Heart rate (HR) was calculated
from the AP wave as previously reported (Sakima et al.,
2005, 2007). Baseline measures of baroreflex sensitivity (BRS)
were established by bolus intravenous injection of 3 doses of
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phenylephrine (2, 5, and 10 µg/kg in 0.9% NaCl) administered
in random order to determine the bradycardic BRS in response
to increases in AP. Bolus dose determinations were used
because this method is more sensitive to alterations in the
parasympathetic baroreflex relative to infusion determinations
(Korner, 1995). A minimum of 15 min was allowed after
baseline measurements before microinjections. Maximum MAP
responses (1MAP, mmHg) and the associated reflex changes in
HR (1HR, bpm) were recorded after each dose of phenylephrine
and compared to the 30-s average during the period immediately
preceding each phenylephrine infusion. 1HR was converted to
changes in pulse interval (1PI, ms) by the formula 60,000/HR.
Bradycardic BRS was defined for each animal as the slope of the
relationship between 1MAP and corresponding 1PI generated
independently from the 3 doses of phenylephrine, as previously
reported (Sakima et al., 2005, 2007; Arnold et al., 2008, 2009).
A minimum of 5 min elapsed between each phenylephrine
infusion to allow normalization of MAP and HR. BRS testing
was repeated within 10 and 60 min of SR141716Amicroinjection
so that each animal served as its own control, with testing
completed within 15 min after starting. In addition, a single
intravenous bolus infusion of phenylbiguanide (10 µg/kg in
0.9% NaCl) was administered following phenylephrine testing
before and after NTS microinjections to assess depression in
HR due to activation of the chemosensitive vagal afferent
fibers.
Spontaneous BRS was also calculated by spectral analysis
of the AP time and frequency domains using the Nevrokard
SA-BRS software (Medistar, Ljubljana, Slovenia), as previously
described (Shaltout and Abdel-Rahman, 2005). Spontaneous BRS
was determined from a minimum of 10 min of AP recordings
obtained during baseline recording and again within 10 min of
SR141716A microinjection, and calculated in the time (Sequence
[Seq] Up, Seq Down, and Seq All; in units of milliseconds per
mmHg) and frequency (low-frequency [LF] and high-frequency
[HF] α indices) domains.
NTS Microinjections
Multi-barreled glass pipettes (outer diameter of 30–50 µm) were
used as previously described (Sakima et al., 2005, 2007; Arnold
et al., 2008, 2009) for NTSmicroinjections. SR141716A (obtained
from the National Institute on Drug Abuse; 0.36 or 36 pmol
[0.167 and 16.7 ng, respectively] in a 120 nL volume of 10%
DMSO in artificial cerebrospinal fluid titrated to pH 7.4) or
vehicle (120 nL) was bilaterally microinjected via pressure from
a hand-held syringe (Becton, Dickinson and Company) into the
NTS [0.4 mm rostral, 0.4 mm lateral to the calamus scriptorius
[caudal tip of the area postrema] and 0.4 mm below the dorsal
surface of the medulla) connected via polyethylene-50 tubing to
a glass micropipette. Air pressure was generated by pushing on
the syringe to displace the desired amount of SR141716A from
the micropipette into the NTS, visualized by movement of the
fluid meniscus across the calibration line of the pipette barrel
as described (Sakima et al., 2005, 2007). The doses and volume
of SR141716A were comparable to previous NTS microinjection
studies in which the drug completely reversed or prevented
alteration of BRS by microinjection of a cannabinoid receptor
agonist (Schaich et al., 2011). At the end of each experiment,
animals were euthanized by intravenous overdose of urethane-
chloralose anesthesia and decapitated. Brains were removed and
frozen on dry ice for verification of the microinjection site in
serial cryostat sections (30 µm) of the frozen medulla (Figure
S1). Only data from injections within the medial NTS at rostro-
caudal level −13.3 to 14.0 mm caudal to bregma are reflected in
the analysis. The accuracy rate for microinjections was> 90%.
Mass Spectrometry Detection of
Anandamide and 2-AG
Medullary tissue was obtained from separate groups of naïve
15-week-old SD, (mRen2)27 and ASrAOGEN rats (n = 4–5
each strain) not used in microinjection experiments. Animals
were decapitated while conscious to avoid potential confounding
effects of anesthesia on brain endocannabinoid levels. Brains
were removed and frozen on dry ice for excision of 3-
mm3 dorsal medullary sections. The sections were obtained
from 1.5 mm anterior to 1.5 mm posterior to the usual
placement of the microinjection pipette, corresponding with
the expected injectate spread within the NTS (Campagnole-
Santos et al., 1988) and including portions of the area
postrema, dorsal motor nucleus, and nucleus gracilis. For
the analysis of the two major endocannabinoids anandamide
and 2-AG, an extraction technique was developed for rat
medulla tissue. Optimal extraction conditions for brain tissue
were obtained using high performance liquid chromatography
(HPLC)-grade acetonitrile and tissue homogenization with
stainless steel beads (2.3 mm, BioSpec Products, Bartlesville,
OK) that reduced enzymatic degradation and attenuated 2-
AG isomerization. Tissue homogenates were fortified with
isotopically-labeled internal standards for 2-AG and anandamide
2-[2H5]2-AG (AG-d5) and [
2H4]anandamide (AEA-d4) on
a per-mg basis for sample integrity and robustness of the
method. The chromatography solvents were Honeywell B&J
HPLC-grade ammonium acetate and acetic acid–double distilled
(Sigma-Aldrich). Stock solutions of anandamide and 2-AG and
their deuterated analogs were freshly prepared and stored as
recommended by the manufacturer. The study samples, quality
control samples, and standards (targeted analysis) were processed
using automated liquid handling to ensure the reproducibility
and consistency of the sample preparation method.
A Waters Acuity ultraperformance liquid chromatography
(UPLC) system (Waters, Milford, MA) equipped with an Acquity
UPLC BEH C18 1.7 µm 2.1 × 50 mm column was utilized for
the separation of endocannabinoids prior to quantitative analysis
by selected reaction monitoring (LC-MS/MS). An API-5000
triple quadrupole mass spectrometer (Applied Biosystems/Sciex,
Carlsbad, CA) was coupled to the UPLC for quantitative analysis,
and operating parameters were optimized for anandamide and
2-AG. Calibration curves spanning the range of quantitation
were produced through least-squares linear regression analysis
of response (analyte integrated area/internal standard integrated
area) vs. concentration, and may be weighted to improve fit,
accuracy and precision. Sample content of anandamide or 2-AG
is expressed as ng analyte per mg tissue wet weight.
Frontiers in Physiology | www.frontiersin.org 3 June 2016 | Volume 7 | Article 207
Schaich et al. Endocannabinoids and Baroreflex Sensitivity
Quantification of CB1, CB2, and CRIP1a
mRNA
RT-qPCR was used to measure mRNA levels of various effector
components of the brain endocannabinoid system, including
CB1 and CB2 receptor, and CRIP1a (Niehaus et al., 2007) in
dorsal medullary tissue from the same naïve 15-week-old SD,
(mRen2)27 and ASrAOGEN rats (n = 4-6 each strain) used for
detection of medullary endocannabinoids. Brains were removed
and frozen on dry ice as described above. Total RNA was
extracted from brain sections using TRIZOL reagent (Invitrogen,
Carlsbad, CA) and was assessed for concentration and stability
using an Agilent 2100 Bioanalyzer with an RNA 6000 nano
LabChip (Agilent Technologies, Palo Alto, CA). Total RNA (1
µg) was reverse transcribed using AMV reverse transcriptase
in a 20-µL reaction mixture containing deoxyribonucleotides,
random hexamers, and RNase inhibitor in reverse-transcriptase
buffer, as described previously (Sakima et al., 2007; Arnold
et al., 2008, 2009). The reaction was terminated by heating the
reverse transcriptase reaction product at 95◦C. For RT-qPCR, 2
µL of resultant cDNA were added to TaqMan Universal PCR
Master Mix (Applied Biosystems) with the appropriate gene-
specific primer/probe set for CB1 and CB2 receptors, and CRIP1a
(Applied Biosystems), and amplification was performed on an
ABI 7000 Sequence Detection System. The mixtures were heated
for 2 min at 50◦ C, 10 min at 95◦C, followed by 40 cycles at
95◦C for 15 s and 60◦C for 60 s. All reactions were performed
in triplicate. 18S ribosomal RNA, amplified using the TaqMan
Ribosomal RNA Control Kit (Applied Biosystems) served as the
internal control. Results were quantified as Ct values, in which
Ct is the threshold cycle of PCR at which an amplified product is
first detected, and was defined as relative gene expression (ratio
of target:control).
Analysis of Data
Values are presented as mean ± SEM. Comparisons of changes
in BRS over time in response to SR141716A or vehicle in the
different strains were assessed using a repeated measures two-
way ANOVA. Where appropriate on the basis of the two-way
ANOVA, one-way ANOVA and post-hoc Bonferroni multiple
comparisons elucidated further differences between strains or
time points. Multiple regression analysis was performed on
BRS scatterplots to determine slopes of fit lines. The criterion
for statistical significance was P < 0.05. Statistical tests were
performed using Prism 5.0 (GraphPad Software, San Diego, CA).
RESULTS
Baseline BRS for Control of HR in
Response to Increases in MAP in SD,
(mRen2)27 and ASrAOGEN Rats
The pooled bradycardic BRS for control of HR at baseline for
ASrAOGEN rats was significantly higher compared to SD rats
(1.43 ± 0.07 vs. 1.03 ± 0.06 ms/mmHg; P < 0.001; n = 11 and
10, respectively; Figure S2), while baseline BRS in (mRen2)27
rats was significantly lower than in SD rats (0.44 ± 0.02
ms/mmHg; P < 0.001; n = 13; Figure S2). These observations
are fully consistent with previous studies from our laboratory
(Sakima et al., 2007; Diz et al., 2008). Furthermore, there were
no differences in baseline BRS values of SD, (mRen2)27 or
ASrAOGEN rat treatment groups receiving vehicle or various
doses of SR141716A (Figure S3).
Effect of CB1 Antagonist on BRS for
Control of HR in SD, (mRen2)27 and
ASrAOGEN Rats
In SD rats, NTS microinjection of 36 pmol of SR141716A had no
effect on BRS for control of HR in response to increases in MAP
produced by phenylephrine at 10 or 60 min after microinjection
(Figure 1). The lower 0.36 pmol dose of SR141716A was not
tested in SD rats due to the lack of effect by the 36 pmol dose.
However, microinjection of 0.36- and 36 pmol of SR141716A into
the NTS of (mRen2)27 rats significantly and dose-dependently
FIGURE 1 | Effect of NTS microinjection of CB1 receptor antagonist
SR141716A on BRS for control of HR evoked by phenylephrine in SD
rats. (A) NTS microinjection of 36 pmol of SR141716A in SD rats did not
significantly change BRS after 10 min, nor after 60 min in the same animals
(n = 5). Note: only the 36-pmol dose of SR141716A was tested in SD rats.
(B) The slope of the relationship between the increases in MAP produced by
phenylephrine and the corresponding reflex bradycardia (1PI) does not show
change from baseline in the linear regression slope 10 min following NTS
microinjection of 36 pmol of SR141716A (1.00 ± 0.08 ms/mmHg baseline;
1.13 ± 0.11 ms/mmHg after 10 min; R2 = 0.84 to 0.92 for pooled data).
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increased BRS by 65% (P < 0.01 vs. baseline) and 100% (P <
0.001 vs. baseline; P < 0.05 vs. 0.36-pmol dose), respectively,
after 10 min (Figures 2A,B). Timecourse experiments showed
that the BRS-enhancing effect of each dose in (mRen2)27 rats was
maintained at 60 min post-microinjection (Figure 2A).
In contrast to the potentiating effect found in (mRen2)27 rats,
NTS microinjection of 0.36 pmol SR141716A in ASrAOGEN
rats significantly reduced cardiac BRS by 43% (P < 0.05 vs.
baseline), while 36 pmol of SR141716A reduced BRS by 67%
after 10 min (P < 0.01 vs. baseline; P < 0.05 vs. 0.36-pmol dose;
Figures 3A,B). As in (mRen2)27 rats, timecourse experiments
showed that the attenuating effect of each dose on BRS was
maintained at 60 min after microinjection (Figure 3A).
Spontaneous BRS (sBRS) values obtained by spectral analysis
of the AP wave following administration of SR141716A in
(mRen2)27 and ASrAOGEN rats are consistent with evoked
FIGURE 2 | Effect of NTS microinjection of SR141716A on BRS for
control of HR evoked by phenylephrine in (mRen2)27 rats. (A) In
(mRen2)27 rats, NTS microinjection of 0.36- (n = 5) and 36-pmol (n = 5) of
SR141716A significantly improved BRS after 10 and 60 min. (B) The 0.36-
and 36- pmol doses produced graded, though not statistically significant,
increases in the slope of the regression line in (mRen2)27 rats (0.47 ± 0.10
ms/mmHg baseline; 0.69 ± 0.10 ms/mmHg 10 min after 0.36 pmol of
SR141716A; 0.79 ± 0.12 ms/mmHg 10 min after 36 pmol SR141716A;
R2 = 0.44 to 0.79 for pooled data). *P < 0.05; **P < 0.01; ††P < 0.01 vs.
baseline; †††P < 0.001 vs. baseline.
BRS measurements. In (mRen2)27 rats SR141716A significantly
improved sBRS (Seq All), including the parasympathetic sBRS
(Seq Up), after both 0.36 and 36 pmol microinjections (P < 0.05;
Table 1), whereas in ASrAOGEN rats 36 pmol of SR141716A
significantly attenuated Seq All and Seq Up (P < 0.05; Table 1).
There was no effect of SR141716A microinjection on the
sympathetic sBRS (Seq Down) in either transgenic strain, nor
were there any changes in sBRS in SD rats (Table 1).
MAP and HR Responses to NTS
Microinjection of CB1 Antagonist
There were no significant differences in baseline MAP or HR
within groups of anesthetized SD, (mRen2)27 or ASrAOGEN
rats receiving vehicle or SR141716A microinjections, nor were
there significant differences between pooled baseline HR of SD
and (mRen2)27 rats receiving vehicle or SR141716A (Table 2 and
Table S1; Figure S4). However, as reported previously, the pooled
FIGURE 3 | Effect of NTS microinjection of SR141716A on BRS for
control of HR evoked by phenylephrine in ASrAOGEN rats. (A) In
ASrAOGEN rats, NTS microinjection of 0.36- (n = 4) and 36-pmol (n = 3) of
SR141716A significantly attenuated BRS after 10 and 60 min. (B) The 0.36-
and 36- pmol doses of SR141716A produced equivalent, statistically
significant reductions in the slope of the regression line in ASrAOGEN rats
(1.42 ± 0.15 ms/mmHg baseline; 0.58 ± 0.27 ms/mmHg 10 min after 0.36
pmol of SR141716A; 0.42 ± 0.04 ms/mmHg 10 min after 36 pmol
SR141716A; P < 0.001; R2 = 0.32 to 0.93 for pooled data). *P < 0.05;
†
P < 0.05 vs. baseline; ††P < 0.01 vs. baseline.
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TABLE 1 | Effects of acute NTS microinjection of SR141716A on indices of spontaneous BRS in SD, (mRen2)27 and ASrAOGEN rats.
Group Seq Up (ms/mmHg) Seq Down (ms/mmHg) Seq All (ms/mmHg) LFα HFα
SD 36 pmol
Baseline 1.58±0.30 1.64± 0.34 1.61± 0.33 1.24± 0.10 1.72±0.45
After SR141716A 2.21±0.45 1.70± 0.38 2.15± 0.43 1.69± 0.46 2.72±0.59
(mRen2)27 0.36 pmol
Baseline 0.86±0.21 0.88± 0.19 0.88± 0.17 1.11± 0.23 0.75±0.83
After SR141716A 1.01±0.28* 1.04± 0.20 1.04± 0.25* 1.37± 0.62 0.83±0.30
(mRen2)27 36 pmol
Baseline 0.77±0.14 0.79± 0.10 0.78± 0.10 0.76± 0.15 0.66±0.16
After SR141716A 1.24±0.27* 1.38± 0.42 1.25± 0.21* 0.79± 0.10 0.91±0.16
ASrAOGEN 0.36 pmol
Baseline 0.99±0.15 1.00± 0.14 0.98± 0.13 1.07± 0.60 1.02±0.20
After SR141716A 0.56±0.10 0.69± 0.10 0.63± 0.09 0.65± 0.24 0.44±0.09*
ASrAOGEN 36 pmol
Baseline 0.97±0.08 0.93± 0.11 0.97± 0.02 1.12± 0.04 0.89±0.09
After SR141716A 0.68±0.06* 0.63± 0.17 0.69± 0.08* 0.78± 0.25 0.64±0.06
Values are mean ± SEM and represent indices of spontaneous BRS measured in the time (Seq Up, Seq Down, Seq All) and frequency (LFα and HFα) domains before and within 10
min of NTS microinjection of SR141716A. *P < 0.05 vs. respective baseline; n = 3–5 all groups.
TABLE 2 | Values of MAP and HR in response to NTS microinjection of
SR141716A.
Group N MAP (mmHg) HR (bpm)
SD 36 pmol SR141716A 5
Baseline 94± 3 297±6
Values at 10 min 90± 3 280±9
Values at 60 min 91± 4 291±11
(mRen2)27 0.36 pmol SR141716A 5
Baseline 103± 5 319±5
Values at 10 min 99± 6 308±5
Values at 60 min 96± 4 326±9*
(mRen2)27 36 pmol SR141716A 5
Baseline 119± 6# 316±5
Values at 10 min 109± 7‡ 318±10*
Values at 60 min 105± 7‡ 325±10*
ASrAOGEN 0.36 pmol SR141716A 4
Baseline 115± 7* 347±12#
Values at 10 min 113± 8# 361±14§
Values at 60 min 104± 4 360±5§
ASrAOGEN 36 pmol SR141716A 3
Baseline 107± 5 335±7
Values at 10 min 104± 7 344±16#
Values at 60 min 98± 6 345±15#
Values are mean ± SEM and represent baseline MAP and HR and values at 10 or 60 min
after the initial SR141716A NTS microinjection; N = number of animals.
‡P < 0.001 vs. baseline.*P < 0.05 vs. SD; #P < 0.01; §P < 0.001.
baseline MAP of anesthetized ASrAOGEN rats was significantly
higher compared to SD rats (115 ± 4 vs. 94 ± 2 mmHg,
respectively; P < 0.01; Figure S4). The pooled baseline HR was
also significantly higher in ASrAOGEN rats compared to SD
and (mRen2)27 rats (347 ± 7 vs. 313 ± 8 and 312 ± 6 bpm,
respectively; P < 0.01; Figure S3). The pooled baseline MAP
of anesthetized (mRen2)27 rats (108 ± 4 ms/mmHg) was also
significantly higher compared to SD rats (P < 0.05; Figure S4).
Acute NTS microinjection of either 0.36 or 36 pmol of
SR141716A did not significantly change resting MAP in SD or
ASrAOGEN rats, nor HR in SD, (mRen2)27 or ASrAOGEN rats
at the time of reflex testing 10 and 60 min after microinjection.
While 0.36 pmol of SR141716A did not have a significant effect
on resting MAP in (mRen2)27 rats over the duration of testing,
the 36 pmol dose produced a modest yet statistically significant
decrease in MAP at 10 and 60 min post-microinjection (P <
0.001 vs. baseline; Table 2). There were no significant effects of
NTS microinjection of vehicle on MAP or HR in any strain
(Table S1). Differences inMAP orHRwithin groups of transgenic
animals from SD rats at individual timepoints are noted in
Table 2 and Table S1.
Microinjection of 36 pmol of SR141716A yielded a modest
yet statistically significant potentiation of intravenous
phenylephrine-induced MAP increases in SD rats after 10
and 60 min (P < 0.05). However, there were no differences in
MAP responsiveness to phenylephrine injections among groups
of (mRen2)27 or ASrAOGEN rats receiving various doses of
SR141716A (Figure S5).
Depressor and bradycardic responses to cardiac
chemosensitive vagal fiber activation induced by intravenous
phenylbiguanide in SD, (mRen2)27 and ASrAOGEN rats were
not altered by NTS microinjection of SR141716 (Figure S6).
Dorsal Medullary 2-AG and Anandamide
Content in SD, (mREN2)27 and ASrAOGEN
Rats
Mass spectrometry revealed that concentrations of 2-AG were
highest in dorsal medulla of (mRen2)27 rats (2.70 ± 0.28 ng/mg
tissue vs. 1.17 ± 0.09 ng/mg tissue in ASrAOGEN rats; P < 0.01;
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n = 4–5; Figure 4A). SD rats had intermediate medullary 2-
AG content (1.85 ± 0.27 ng/mg tissue; n = 5), falling short of
statistical significance compared to (mRen2)27 rats (P = 0.069)
and ASrAOGEN rats (P = 0.052). Dorsal medullary anandamide
was found in levels 1000-fold lower than 2-AG and there were no
significant differences among rat strains (Figure 4B).
CB1, CB2 and CRIP1a mRNA in SD,
(mREN2)27 and ASrAOGEN Rats
Relative gene expression of CB1 and CB2 receptors, and the
endocannabinoid regulatory protein CRIP1a was measured in
dorsal medullary tissue of naïve SD (n = 5), (mRen2)27 (n= 4),
and ASrAOGEN (n = 6) rats at 15 weeks of age (Figure 5).
CB1 receptor mRNA was approximately 0.25-fold lower in the
dorsal medulla of ASrAOGEN rats relative to SD (P < 0.01)
and (mRen2)27 (P < 0.05) rats (Figure 5A). There were no
differences in relative mRNA levels of CB2 receptor or CRIP1a
among the same rat groups (Figures 5B,C).
DISCUSSION
In this study, we report for the first time the endocannabinoid
content and relative receptor mRNA levels associated with the
FIGURE 4 | 2-AG and anandamide content in dorsal medulla of SD,
(mRen2)27 and ASrAOGEN rats. (A) Mass spectrometry revealed levels of
2-AG were significantly higher in the dorsal medullary tissue of 15-week-old
(mRen2)27 rats (n = 5) relative to ASrAOGEN rats (n = 4). (B) Anandamide
was detected at levels 1000-fold lower than 2-AG in the same tissue samples,
and there were no significant differences among strains. **P < 0.01 vs.
ASrAOGEN.
endocannabinoid system are differentially expressed in the dorsal
medulla of (mRen2)27 and ASrAOGEN rats compared to SD
rats. We also determined the effects of CB1 cannabinoid receptor
blockade by SR141716A at the level of the NTS on cardiac
BRS in response to phenylephrine-evoked increases in MAP
in anesthetized rats with differential brain RAS expression
profiles. The improvement in BRS in response to SR141716A
in (mRen2)27 rats with higher 2-AG content in the dorsal
medulla suggests that higher brain Ang II (Senanayake et al.,
1994) may contribute to upregulation of 2-AG release resulting
in the blunted baseline BRS in this strain. Our findings are
consistent with the finding that the effects of Ang II in the
NTS to attenuate BRS are blocked by a CB1 receptor antagonist
(Diz et al., 2015). In ASrAOGEN rats, however, medullary 2-AG
content was significantly lower compared to (mRen2)27 rats,
and CB1 receptor mRNA was significantly lower relative to SD
and (mRen2)27 rats. Therefore, the BRS-suppressing effect of
SR141716A in the NTS of ASrAOGEN rats suggests differential
regulatory functions of the brain endocannabinoid system in rats
with high or low brain RAS expression.
Our present study presents evidence for a direct action
of endocannabinoids to modulate baroreflex function in
transgenic rats over- or underexpressing components of the
brain RAS. Microinjection of the selective CB1 receptor
antagonist SR141716A (0.36 and 36 pmol) into the NTS
differentially altered BRS measured as the bradycardic response
to phenylephrine-evoked increases in AP in (mRen2)27 rats
with Ang II-dependent hypertension and in glial Aogen-deficient
ASrAOGEN rats. In (mRen2)27 rats, the 0.36-pmol dose of
SR141716A significantly improved BRS, and the 36-pmol dose
improved BRS from baseline to a greater degree, indicating a
dose-response relationship. In fact, the 36-pmol dose improved
BRS in these animals to ≈1.05 ms/mmHg, a level comparable
with baseline BRS of SD rats and suggesting normalization
of cardiac BRS in (mRen2)27 rats (Schaich et al., 2014). In
ASrAOGEN rats, however, SR141716A significantly impaired
BRS to ≈0.46 ms/mmHg, a level often observed in hypertension
and comparable to baseline BRS of (mRen2)27 rats (Diz et al.,
2008). Although it is difficult to determine whether CB1 receptor
blockade affects resting MAP in anesthetized ASrAOGEN rats
due to a small group size, a significant decrease in BRS was
clearly detected. The differential BRS responses to CB1 receptor
antagonism in the NTS of these strains with altered brain
endocannabinoid content supports the prior observations of
differential baroreflex-evoked responses to exogenously applied
CB1 agonists in hypertensive vs. normotensive animals that may
involve contrasting effects on amino acid transmitter systems
(Brozoski et al., 2009). Thus, data are consistent with the
interpretation that the medullary endocannabinoid system exerts
a tonic influence over baroreflex function via NTS CB1 receptors
which may contribute to suppressed baseline cardiovagal BRS
in (mRen2)27 rats and enhanced baseline BRS in ASrAOGEN
rats. Future studies are required to determine the mechanisms
underlying these effects.
Unlike in the transgenic animals, there was no effect of
CB1 receptor blockade by 36 pmol of SR141716A in the NTS
on BRS for control of HR in SD rats. This is in line with
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FIGURE 5 | CB1, CB2 and CRIP1a mRNA in the dorsal medulla of SD, (mRen2)27 and ASrAOGEN rats. (A) Relative gene expression of CB1 receptor was
lower in the dorsal medullary tissue of 15-week-old ASrAOGEN rats (n = 6) compared to SD (n = 5) and (mRen2)27 (n = 4) rats. (B,C) No significant differences in
relative gene expression of CB2 receptor (B) or CRIP1a (C) were found among strains. *P < 0.05 vs. (mRen2)27;
†
P < 0.01 vs. SD.
previous observations by others that NTS microinjection of
SR141716A alone in dogs did not affect BRS (Rademacher
et al., 2003), nor did the CB1-selective antagonist AM281 by
itself alter sympathetic nerve discharge in SD rats (Durakoglugil
and Orer, 2008). Lack of responses may indicate minimal or
absent tonic influence of the endocannabinoid system over
baroreflex function in normotensive animals, or that baseline
CB1 receptor modulation of the baroreflex in SD rats reflects
balanced effects on GABA and glutamate release (Seagard et al.,
2004; Chen et al., 2010). In fact, glutamate levels are significantly
higher in the dorsal medulla of ASrAOGEN rats relative to
(mRen2)27 rats as measured by proton magnetic resonance
spectroscopy (Garcia-Espinosa et al., 2010). It is also possible
that this reflects a compensatory balance of additional factors in
the NTS, such as endovanilloids (Derbenev et al., 2006), leptin
(Arnold et al., 2009), serotonin (Nalivaiko and Sgoifo, 2009),
and nonesterified fatty acids (Shaltout and Abdel-Rahman, 2005)
that may potentially influence baroreflex function. Although
medullary endocannabinoids maymodulate BRS through actions
at transient receptor potential vanilloid type 1 channels in the
NTS or dorsal motor nucleus (Anwar and Derbenev, 2013), our
studies emphasize the contribution of CB1 receptors in baroreflex
modulation, because SR141716A is a selective CB1 receptor
antagonist that is not reported to interact with other receptors,
including CB2 receptors (Rinaldi-Carmona et al., 1995).
Measurements of spontaneous BRS obtained by spectral
analysis of the AP wave before and after NTS CB1 receptor
blockade agree with the results of our evoked BRS measurements
using the phenylephrine ramp method, providing additional
evidence for altered CB1 receptor tone in the NTS of (mRen2)27
and ASrAOGEN rats. Analysis of the individual sympathetic (Seq
Down) and parasympathetic (Seq Up) time sequences of sBRS
revealed significant alterations only to Seq Up in the transgenic
animals following administration of SR141716A, suggesting that
NTS CB1 receptors may preferentially modulate BRS in response
to increases in AP since the up-sequence is an accepted measure
for tonic cardiac parasympathetic control (Wang et al., 2004).
BRS values obtained by the spontaneous as compared with
evoked methods reflect changes over a much smaller range
(beat-to-beat) in a closed-loop model. Despite differences in
the two methods, a highly significant correlation exists between
them (Shaltout and Abdel-Rahman, 2005), especially with vagal
components, as illustrated in this study and a recent study in
older SD rats, which also found comparable results between
the evoked and spectral analysis methods (Schaich et al., 2015).
Furthermore, the absence of alterations in chemosensitive vagal
fiber responses supports the specificity of SR141716A actions
on BRS because these responses are mediated by chemoreceptor
fibers that converge with baroreceptor inputs within the NTS
(Paton, 1998).
We found that 2-AG content was highest in dorsal brainstem
of (mRen2)27 rats and lowest in ASrAOGEN rats, which may
be a potential mechanism contributing to differential resting
BRS among SD, (mRen2)27 and ASrAOGEN rats. Anandamide
may also play an important role in this region, but its detection
at 1000-fold lower levels without significant differences among
strains suggests that 2-AG is likely the more functionally
significant endocannabinoid with respect to CB1-mediated BRS
modulation at the level of the NTS in the face of altered brain
Ang II/Ang-(1-7) balance. We further observed a significantly
lower expression of CB1 receptor mRNA in dorsal medullary
tissue of ASrAOGEN rats relative to SD and (mRen2)27 rats.
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Together, these observations suggest differential regulation of
the endocannabinoid system in dorsal medulla of (mRen2)27
and ASrAOGEN rats, respectively, paralleling the relative
expression of RAS components in these animals. In (mRen2)27
rats, the higher dorsal medullary 2-AG levels may reflect
increased production (Szekeres et al., 2012), increased activity
of enzymes involved in its biosynthesis, such as diacylglycerol
lipase, or downregulation of its primary degradative enzyme
monoacylglycerol lipase (Di Marzo, 2008) as the principal drivers
of upregulated CB1 receptor tone in this region. Our data
are consistent with evidence for upregulated endocannabinoid
tone that is widely reported in acute and chronic animal
models of cardiovascular disease, including atherosclerosis and
hypertension (Pacher et al., 2005; Sugamura et al., 2009; Naito
et al., 2010).
Although dorsal medullary expression of CB1 receptor in
(mRen2)27 rats did not differ from SD rats, enhanced sensitivity
of the receptor cannot be ruled out as an additional mechanism
for upregulated CB1 receptor tone in this strain because Ang
II-induced increased expression of Gi protein isoforms is
reported in SHR (Marcil et al., 1997) and one-kidney one-
clip hypertension (Ge et al., 2006). It is also possible that an
interaction between CB1 and Ang II type 1 (AT1) receptors
enhances the pathogenic signaling of Ang II, as previously
described (Rozenfeld et al., 2011). In ASrAOGEN rats, lower
levels of 2-AG and CB1 receptor mRNA suggest a more general
downregulation of the dorsal medulla endocannabinoid system
that may contribute to the enhanced baseline BRS for control
of HR in these animals. Whether the differential expression
of the CB1 receptor and production of 2-AG in the dorsal
brainstem of (mRen2)27 and ASrAOGEN rats is attributable to
a direct interaction with the RAS or an indirect effect is currently
unknown; however, transactivation of CB1 by AT1 receptors
and direct stimulation of 2-AG production by Ang II has been
observed in vitro (Turu et al., 2007, 2009). Although we detected
CB2 receptor mRNA in the NTS, it is likely not involved in BRS
modulation because previous studies in our laboratory with the
non-selective cannabinoid receptor agonist CP55,940 show all
effects on BRS in SD rats are completely blocked or reversed
by the CB1 antagonist SR141716A (Schaich et al., 2011). It is
also unlikely that the CB1-associated protein CRIP1a, believed
to serve an autoinhibitory function for CB1 receptors (Niehaus
et al., 2007), is a primary contributor to differential modulation
of BRS because we did not detect significant differences in mRNA
expression among the three rat strains.
We cannot exclude the possibility that the spread of the
SR141716A injection may have accessed neighboring brainstem
nuclei, such as the area postrema or the dmnX, for effects on
BRS. However, microinjection of 125I-Sar-Thr Ang II at this
volume was mostly confined to the NTS (Campagnole-Santos
et al., 1988), and functional assessments showed that 50 nL of
an AT1 receptor antagonist injected into the dmnX did not alter
responses to NTS microinjection of Ang II (Fow et al., 1994).
The injection of SR141716A accessed NTS neuronal cell bodies
as well as presynaptic vagal afferents and other terminals for
projecting pathways within the NTS, so it is not clear which
elements mediate the effects on BRS. However, Ang II exerts
actions on BRS at neuronal cell fibers, glial and vascular elements
in the NTS (Barnes et al., 2003).
We also cannot exclude the possibility that weak inverse
agonist properties of SR141716A are reflected in our present
data (Pertwee, 2005). Maximal inhibition of constitutive G-
protein activity by SR141716A ranged from 20 to 40% at
micromolar concentrations depending on brain region in rats,
although effects in brainstem were not assessed (Sim-Selley et al.,
2001). However, it is unclear if this property of SR141716A
yields functionally significant actions in vivo. For example,
SR141716A by itself only slightly reduced neuronal discharge
in rat locus coeruleus (Muntoni et al., 2006), and in the NTS
of dogs SR141716A had no effect on baseline AP or resting
sympathetic BRS (Rademacher et al., 2003), fully consistent
with our present data in SD rats. Potential inverse agonism
effects notwithstanding, the increased levels of 2-AG we detected
in dorsal brainstem of (mRen2)27 rats are consistent with a
competitive antagonist effect of SR141716A in NTS to improve
BRS, while the impairments to BRS in ASrAOGEN rats by
SR141716A are too large to attribute to an inverse agonist
effect.
We investigated changes in cardiovagal BRS, MAP and HR
in response to acute, site-specific CB1 receptor blockade in
rats with up- or downregulated brain RAS expression. Our
results support our hypothesis for differential expression of
brain endocannabinoid system components paralleling the brain
RAS expression in these animals. The novel finding that NTS
CB1 receptor blockade produces opposite effects in rats over-
or under-expressing components of the brain RAS may have
implications for understanding the mechanisms of autonomic
reflex control of HR and blood pressure in pathological
conditions that are in part dependent on an activated brain
RAS, such as hypertension. In fact, chronic systemic treatment
with SR141716 lowered blood pressure and improved BRS in
transgenic (mRen2)27 rats (Schaich et al., 2014) and the present
data implicate the NTS as at least one brain site contributing
to these effects. Chronic selective peripheral and central CB1
receptor blockade is required to further evaluate the role of
endocannabinoid-mediated BRS impairments in pathologies
associated with altered circulating, cerebrospinal fluid, or brain
tissue RAS.
Perspectives
The impairment of BRS for control of heart rate, an index of
vagus nerve function, often precedes the onset of hypertension
and stroke (Thayer and Lane, 2007) and is a common feature
of cardiovascular risk factors, including obesity and aging
(Thayer et al., 2010). Identifying factors that modulate baroreflex
function is therefore important for understanding predisposition
or progression of these negative conditions. The present data
suggest an upregulated brain endocannabinoid system in Ang
II-dependent hypertension associated with a deficiency in the
counterbalancing actions of Ang-(1-7) may contribute to the
impaired BRS typical of these conditions, and that blockade of
CB1 receptors improves BRS. We observed a similar pattern
in older SD rats with age-related impairments in BRS known
to be associated with Ang-(1-7) deficiency with the NTS
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(Schaich et al., 2015). CB1 receptor blockade within the NTS
restored BRS to levels similar to younger SD rats and this
was associated with elevated 2-AG content in dorsomedial
medulla of the older rats (Schaich et al., 2015). Therefore,
CB1 receptor-mediated impairments in BRS resulting from
increased endocannabinoid productionmay contribute to factors
permissive in the development of elevated AP in populations with
elevated Ang II and/or deficiencies in Ang-(1-7). The positive
metabolic effects of chronic systemic CB1 receptor blockade in
obese or diabetic humans and animals are well known (Van
Gaal et al., 2005). The results of our present study suggest that
chronic systemic administration of a CB1 receptor antagonist
may have additional, positive autonomic or cardiovascular effects
in hypertension accompanied by impaired metabolic function.
Further understanding of the consequences and mechanisms
of an upregulated endocannabinoid system in hypertension
will be important for therapeutic targeting of all features of
cardiovascular disease.
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